MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 555217 | Name: HMN-154
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

HMN-154 is a benzenesulfonamide anticancer agent. HMN-154 inhibits DNA binding of NF-Y to the human major histocompatibility complex class II human leukocyte antigen DRA Y-box sequence in a dose-dependent manner.

Chemical Structure

HMN-154
HMN-154
CAS#173528-92-2

Theoretical Analysis

MedKoo Cat#: 555217

Name: HMN-154

CAS#: 173528-92-2

Chemical Formula: C20H18N2O3S

Exact Mass: 366.1038

Molecular Weight: 366.44

Elemental Analysis: C, 65.56; H, 4.95; N, 7.65; O, 13.10; S, 8.75

Price and Availability

Size Price Availability Quantity
100mg USD 950.00 2 Weeks
200mg USD 1,450.00 2 Weeks
500mg USD 1,950.00 2 Weeks
1g USD 2,950.00 2 Weeks
2g USD 4,650.00 2 Weeks
5g USD 7,250.00 2 Weeks
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
HMN-154; HMN 154; HMN154.
IUPAC/Chemical Name
(E)-4-(2-(2-(N-(4-Methoxybenzenesulfonyl)amino)phenyl)ethenyl)pyridine
InChi Key
CIJCDFMGZYKSSC-VOTSOKGWSA-N
InChi Code
InChI=1S/C20H18N2O3S/c1-25-18-8-10-19(11-9-18)26(23,24)22-20-5-3-2-4-17(20)7-6-16-12-14-21-15-13-16/h2-15,22H,1H3/b7-6+
SMILES Code
O=S(NC1=CC=CC=C1/C=C/C2=CC=NC=C2)(C3=CC=C(OC)C=C3)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
HMN-154 is a novel benzenesulfonamide anticancer compound; inhibits KB and colon38 cells with IC50 values of 0.0026 and 0.003 μg/mL, respectively.
In vitro activity:
Furthermore, HMN-154 inhibits DNA binding of NF-Y to the human major histocompatibility complex class II human leukocyte antigen DRA Y-box sequence in a dose-dependent manner. Reference: Mol Pharmacol. 1999 Feb;55(2):356-63. https://pubmed.ncbi.nlm.nih.gov/9927629/
In vivo activity:
TBD
Solvent mg/mL mM
Solubility
DMSO 15.0 40.93
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 366.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Tanaka H, Ohshima N, Hidaka H. Isolation of cDNAs encoding cellular drug-binding proteins using a novel expression cloning procedure: drug-western. Mol Pharmacol. 1999 Feb;55(2):356-63. doi: 10.1124/mol.55.2.356. PMID: 9927629.
In vitro protocol:
1. Tanaka H, Ohshima N, Hidaka H. Isolation of cDNAs encoding cellular drug-binding proteins using a novel expression cloning procedure: drug-western. Mol Pharmacol. 1999 Feb;55(2):356-63. doi: 10.1124/mol.55.2.356. PMID: 9927629.
In vivo protocol:
TBD
1: Tanaka H, Ohshima N, Hidaka H. Isolation of cDNAs encoding cellular drug-binding proteins using a novel expression cloning procedure: drug-western. Mol Pharmacol. 1999 Feb;55(2):356-63. PubMed PMID: 9927629.